Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours

• Published in: Drugs in R&D 2021-03, Vol.21 (1), p.103-111
• Main Authors: Vermunt, Marit A. C., de Weger, Vincent A., Janssen, Julie M., Lopez-Yurda, Marta I., Keessen, Marianne, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Marchetti, Serena
• Format: Article
• Language: English
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT03147378; Original; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy
• ISSN: 1174-5886; 1179-6901
• DOI: 10.1007/s40268-020-00336-x

Introduction ModraDoc006 is a novel docetaxel tablet formulation that is co-administrated with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Objectives This study evaluated the effect of food consumed prior to administration of ModraDoc006/r on the pharmacokinetics of docetaxel and ritonavir. Methods Patients with advanced solid tumours were enrolled in this randomized crossover study to receive ModraDoc006/r in a fasted state in week 1 and after a standardized high-fat meal in week 2 and vice versa. Pharmacokinetic sampling was conducted until 48 h after both study drug administrations. Docetaxel and ritonavir plasma concentrations were determined using liquid chromatography with tandem mass spectrometry. Safety was evaluated with the Common Terminology Criteria for Adverse Events, version 4.03. Results In total, 16 patients completed the food-effect study. The geometric mean ratio (GMR) for the docetaxel area under the plasma concentration–time curve (AUC) 0–48 , AUC 0–inf and maximum concentration ( C max ) were 1.11 (90% confidence interval [CI] 0.93–1.33), 1.19 (90% CI 1.00–1.41) and 1.07 (90% CI 0.81–1.42) in fed versus fasted conditions, respectively. For the ritonavir C max , the GMR was 0.79 (90% CI 0.69–0.90), whereas the AUC 0–48 and AUC 0–inf were bioequivalent. The most frequent treatment-related toxicities were grade ≤ 2 diarrhoea and fatigue. Hypokalaemia was the only observed treatment-related grade 3 toxicity. Conclusions The docetaxel and ritonavir exposure were not bioequivalent, as consumption of a high-fat meal prior to administration of ModraDoc006/r resulted in a slightly higher docetaxel exposure and lower ritonavir C max . Since docetaxel exposure is the only clinically relevant parameter in our patient population, the overall conclusion is that combined ModraDoc006 and ritonavir treatment may be slightly affected by concomitant intake of a high-fat meal. In view of the small effect, it is most likely that the intake of a light meal will not affect the systemic exposure to docetaxel. ClinicalTrials.gov Identifier NCT03147378, date of registration: May 10 2017.